VC
VRDN icon

Vivo Capital’s Viridian Therapeutics VRDN Stock Holding History

Vivo Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.25M Sell
166,288
-816,288
-83% -$24.2M 0.27% 41
2025
Q4 		$30.6M Hold
982,576
– – 1.98% 18
2025
Q3 		$21.2M Hold
982,576
– – 1.71% 19
2025
Q2 		$13.7M Hold
982,576
– – 1.41% 12
2025
Q1 		$13.2M Hold
982,576
– – 1.75% 9
2024
Q4 		$18.8M Sell
982,576
-695,631
-41% -$15.1M 2.11% 9
2024
Q3 		$38.2M Hold
1,678,207
– – 3.16% 9
2024
Q2 		$21.8M Hold
1,678,207
– – 2.02% 10
2024
Q1 		$29.4M Hold
1,678,207
– – 2.31% 11
2023
Q4 		$36.6M Hold
1,678,207
– – 2.99% 9
2023
Q3 		$25.7M Hold
1,678,207
– – 2.82% 11
2023
Q2 		$39.9M Hold
1,678,207
– – 2.76% 8
2023
Q1 		$42.7M Hold
1,678,207
– – 2.96% 6
2022
Q4 		$49M Buy
1,678,207
+18,188
+1% +$419K 5.64% 3
2022
Q3 		$34M Buy
1,660,019
+360,019
+28% +$6.47M 3.76% 10
2022
Q2 		$15M Hold
1,300,000
– – 1.51% 16
2022
Q1 		$24M Hold
1,300,000
– – 1.66% 12
2021
Q4 		$25.7M Hold
1,300,000
– – 1.55% 15
2021
Q3 		$21.4M Buy
+1,300,000
New +$19.1M 0.96% 23

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vivo Capital's VRDN Position: Q1 2026 in Review

Vivo Capital reduced its Viridian Therapeutics (VRDN) stake by 83% in Q1 2026, selling an estimated $24.2M and leaving 166,288 shares worth $3.25M. The position accounts for 0.27% of the portfolio, ranked #41.

Vivo Capital first reported a position in VRDN in Q3 2021 and has held it in 19 quarters since. The position peaked at $49M in Q4 2022. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Vivo Capital held 166,288 shares of Viridian Therapeutics worth $3.25M as of Q1 2026.
  • Vivo Capital sold 816,288 Viridian Therapeutics shares in Q1 2026, an estimated $24.2M.
  • Viridian Therapeutics made up 0.27% of Vivo Capital's portfolio in Q1 2026, its #41 holding.
  • Vivo Capital first reported a position in Viridian Therapeutics in Q3 2021 and has held it in 19 quarters since.
  • Vivo Capital's Viridian Therapeutics position peaked at $49M in Q4 2022.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.